Abstract:
The present invention relates to Azetidinone Derivatives, compositions comprising an Azetidinone Derivative and methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease, comprising administering to a patient an effective amount of an Azetidinone Derivative.
Abstract:
This invention discloses novel gamma secretase inhibitors of the formula: R 2 and R 3 , or R 2 and R 4 , or R 3 and R 4 , together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substituents. One or more compounds of formula (I), or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.
Abstract:
The present invention relates to Azetidinone Derivatives, compositions comprising an Azetidinone Derivative and methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease, comprising administering to a patient an effective amount of an Azetidinone Derivative.
Abstract:
In its many embodiments, the present invention provides a novel class of heterocyclic compounds of the formula: as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.
Abstract:
Disclosed are compounds of the formula (I): and compounds of the formula (IIA): wherein R 1 , R 2 , R 3 , R 4 , R 5 , u and v are as defined herein. These compounds can be used in methods of treating pain (e.g., inflammatory pain, chronic pain, and neuropathic pain), methods of treating diabetes, and methods of inhibiting the absorption of cholesterol.
Abstract translation:公开了式(I)的化合物:和式(IIA)的化合物:其中R 1,R 2,R 3, R 4,R 5,u和v如本文所定义。 这些化合物可以用于治疗疼痛(例如炎性疼痛,慢性疼痛和神经性疼痛)的方法,治疗糖尿病的方法和抑制胆固醇吸收的方法。
Abstract:
In its many embodiments, the present invention provides tricyclic compounds of formula (I) (wherein J 1 -J 3 , X, Z, and R 1 , R 3 , and R 4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
Abstract:
In its many embodiments, the present invention provides novel heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.
Abstract:
Disclosed are compounds of formula (I) wherein Z 1 is -CH 2 - or -C(O)-, R 4 and R 5 are carbon chains (and optionally, together can form a C 2 bridge), u and v are independently an integer of 0-3 such that there sum is from 3 to 5, and R 2 is heteroaryl, and R 1 and R 3 are as defined herein. Also disclosed are methods of treating pain using a compound of formula (I).
Abstract translation:公开了式(I)的化合物,其中Z 1是-CH 2 - 或-C(O) - ,R 4和R 4, SUP> 5是碳链(并且可选地,一起可以形成C 2 H 2桥),u和v独立地是0-3的整数,使得总和为3至5 R 2是杂芳基,R 1和R 3如本文所定义。 还公开了使用式(I)化合物治疗疼痛的方法。
Abstract:
This invention discloses novel gamma secretase inhibitors of the formula: R 2 and R 3 , or R 2 and R 4 , or R 3 and R 4 , together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substituents. One or more compounds of formula (I), or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.